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Abstract

Nail psoriasis affects a large number of patients with psoriasis and has a major
psychosocial impact. Furthermore, it may be regarded as a predictor of more severe
forms of psoriasis and early sign of psoriatic arthritis. The clinical presentations
vary depending on the structure affected (nail matrix or nail bed), the nail lesions
may range from minor to severe, but they are not specific. Treatment is a challenge,
in most cases the lesions being resistant to therapy.
We present a rare case of psoriasis with nail onset in a 59-year-old woman. The
nail involvement confined to the fingernails was severe, with significant
impairment of the patient’s quality of life. Conventional therapies failed to improve
the nail lesions, but a marked improvement was achieved under etanercept therapy.
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Acne conglobata is a rare, severe form of acne vulgaris characterized by the presence of comedones,
papules, pustules, nodules and sometimes hematic or meliceric crusts, located on the face, trunk, neck, arms
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and buttocks.

Case Report
We report the case of a 16 year old Caucasian female patient from the urban area who addressed our
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Introduction

further contributing to this problem. As a result,

Psoriasis is a chronic immune-mediated disorder
affecting about 2% of the general population. The
pathogenic mechanisms involved in the development of

systemic therapy is often necessary (10).

Case Report
A 59-year-old woman was admitted to our clinic for

psoriasis lesions are related to the activation of the nail changes and erythemato-squamous lesions located
immune system, which leads to the release of on the tips of her fingers. She stated that the first nail
proinflammatory cytokines, such as TNF alpha, IL17, changes had started six months earlier and shortly
12, 23, etc. These mediators of inflammation stimulate afterwards, the skin lesions appeared on her fingers. The
processes such as excessive keratinocyte proliferation
and angiogenesis, promoting the occurrence of psoriasis

mycological examination that was negative and a skin
biopsy that established the diagnosis of dyshidrotic

lesions (1, 2).
Most patients with psoriasis develop nail lesions
during the course of the disease, the prevalence of nail
psoriasis among patients with psoriasis ranging between
10 and 78%, with a mild male predominance (3).
Approximately 1-5% of patients present nail lesions
without skin manifestations (4). However, studies have
shown that many patients who initially had only nail
involvement developed skin or joint lesions later (5).
Nail

patient addressed a dermatologist who performed a

psoriasis

involves

the fingernails

more

eczema. Keratolytics and topical corticoids were
prescribed. The anamnesis revealed that her father had
psoriasis vulgaris. The patient had no relevant history of
medical or surgical conditions.
At the time of presentation to our clinic, the physical
examination revealed hyperkeratotic nails, with a brownyellowish appearance and subungual deposit, painful on
palpation. Erythemato-squamous lesions, moderately
pruritic, localized especially on the tips of her fingers,
were also observed (Figure 1).

frequently than the toenails (3). Clinical signs vary
depending on the structure affected. If the lesions are
confined to the nail matrix, pitting (cupuliform
depressions), leukonychia, red spots in the lunula, or nail
crumbling may occur. Nail bed lesions lead to
onycholysis,

subungual

hyperkeratosis,

splinter

hemorrhages, oil drop discoloration, and nail thickening.
Nail pitting is the most common sign encountered in nail
psoriasis (6-8). These changes are not specific and may
also occur in other disorders (9).
NAPSI (spell out the first time?) is the most
commonly used index for assessing the severity of nail
psoriasis. The method involves the division of the nail
into four quadrants by drawing imaginary lines (a
vertical and a horizontal line) and the evaluation of the
matrix and nail bed lesions in each quadrant (3, 9).
Treatment is difficult due to the low penetration of
topical treatments in the nail, the pathologic changes

Figure 1. Hyperkeratotic nails, with a brown-yellow
appearance and subungual deposit, erythematosquamous lesions, localized especially on the tips of
her fingers
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The toenails were not involved. Otherwise the required criteria, the patient was started on etanercept.
clinical examination was
normal.
Laboratory The evolution was rapid and favorable, a 75%
investigations did not show any significant abnormality.

improvement in PASI score was observed after six

The main differential diagnoses included skin months of treatment. After 8 months of treatment, PASI
score was 5, DLQI score 5, and NAPSIscore 32
conditions associated with nail involvement such as
(Figurek3).
palmar eczema, psoriasis vulgaris, lichen planus, and
alopecia

areata. We established the presumptive

diagnosis of psoriasis vulgaris, given her positive family
history and clinical examination. We decided to perform
another biopsy, but the result was inconclusive. We
initiated treatment with acitretin, as many studies have
demonstrated

a

beneficial

effect

on

subungual

hyperkeratosis and multiple nail involvement.
After 2 months, well defined erythemato-squamous,
slightly pruritic lesions occurred predominantly on her
lower limbs. A biopsy from her left calf was taken,
confirming the diagnosis of psoriasis vulgaris. The
histopathologic

examination

showed

parakeratosis,

epidermal micro-abscesses with neutrophils, acanthosis
and papillomatosis; in the papillary dermis a dense
lymphocytic

infiltrate

perivasculary

was

predominantly

noticed.

Regarding

disposed
the

nails’

appearance, no satisfactory results were observed after
the treatment with acitretin (Figure 2).

Figure 3. The clinical aspect after 8 month of etanercept
therapy

Discussion
It seems that nail involvement in psoriasis is much
more common than previously thought. Studies have
shown that nail psoriasis is positively associated with
both duration and severity of the disease (4, 11).
Furthermore numerous studies have revealed a strong
correlation between nail psoriasis and psoriatic arthritis;

Figure 2. The clinical aspect after 8 weeks of treatment
with acitretin

Therefore we decided to stop acitretin and start

63-83% of the patients with psoriatic arthritis present
nail changes (12). Some authors have suggested that nail
psoriasis could be considered a predictor of the

methotrexate. After 6 months, the clinical evaluation development of psoriatic arthritis (13). In the presented
revealed extensive erythemato-squamous lesions and a case, the patient had not developed joint lesions yet.
modest relief of nail lesions. We considered the

Nail psoriasis has a significant impact on the

initiation of the biological therapy. PASI score was 24.8, patient’s quality of life, in some cases interfering even
DLQI score 24, and NAPSI score72. Meeting the with the simplest daily activities (10). In a large study, a
188
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questionnaire was applied to 1,728 subjects with on the patient’s quality of life, interfering with the daily
psoriasis; 1,379 of them had nail lesions, with activities (6, 17).
involvement of both finger and toenails. Regarding
In our case, we opted for acitretin given the
patients with nail lesions, 93% felt a significant cosmetic extensive nail lesions, characterized by an important
handicap, 60% reported interferences with their daily hyperkeratosis, associated with skin lesions on the tip of
and professional activities, and 51.8%complained of
pain (14). In the study by Klaasen (15), the impact on
the quality of life of patients with nail psoriasis was
assessed using DLQI and NPQ10, with higher scores
among women obtained. Psoriasis had a significant
impact on the quality of life, with results similar to those
obtained in patients with cardiovascular disease,
diabetes, or depression (15). In our case, the patient’s

the fingers. Ricerri reported a case of psoriasis in a 73year-old patient with severe nail psoriasis involving all
fingernails and toenails successfully treated with
acitretin (0.5 mg/kg). He associated urea-based lacquer
as adjuvant treatment (18). Tosti reported a 41%
reduction in the NAPSI score among patients treated
with acitretin, the first improvement in the clinical

quality of life was dramatically reduced, the disease appearance being observed after 4-8 weeks of treatment
interfering with the simplest daily activities. In addition, (19). However, acitretin may lead to onycholysis and
the patient had a tendency toward social isolation.

nail fragility, sodoses should beas low as possible (20).

In a recent study, a positive family history of In our case after 8 weeks of treatment, no satisfactory
psoriasis was more common in the case of those with results were observed and further skin lesions developed.
nail lesions compared to those without nail lesions Thus we cease dacitretin
(53.7% vs. 42.8%). Furthermore, a significant methotrexate treatment.
percentage of those with nail lesions had an early onset

treatment

and

began

Several studies have demonstrated the efficacy of

of psoriasis (under the age of 40 years) (4). Regana et al. methotrexate on nail psoriasis; the favorable results are
have revealed a positive relationship between the probably based on the drug action on T-lymphocytes (8).
severity of nail lesions and being 65 years or older, as For example, patients with nail psoriasis who received
well as a positive family history of psoriasis or type of 15mg/weekly of methotrexate showed a reduction in the
psoriasis, most of whom suffered from moderate-severe NAPSI score of43.3% after 24 weeks of treatment. In
psoriasis (16). Our patient had a positive family history, the same study,patients treated with cyclosporine
her father suffering from psoriasis.

showed a 37% mean improvement in the NAPSI score

Our case illustrates the difficulty in treating nail (21). However, in other studies cyclosporine was
psoriasis, multiple therapies being often necessary until a superior to methotrexate (16). In our case, six months
satisfactory response is achieved. In mild and moderate after starting treatment with methotrexate, results were
forms of nail psoriasis, local therapy is the first choice. not satisfactory and we decided to initiate therapy with a
Systemic therapy is recommended when nail psoriasis is biological agent. Biological agents have proven their
associated with extensive cutaneous psoriasis lesions, if efficacy in both cutaneous and nail lesions. Infliximab,
the lesions are severe or involve several nails (5 out of adalimumab and etanercept are the most studied
10 or more), and if the disease has a significant impact treatments; we decided to give our patient etanercept.
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Regana et al. have shown that classical treatments
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